



Cardiovascular magnetic resonance 
myocardial perfusion: methods and applications 
in patients with coronary artery disease
INTRODUCTION                                                               
Cardiovascular disease is the main cause of death in most European 
countries, with a range of mortality rates between different countries 
(<3 per 1,000 inhabitants in the South-Western and Northern Europe 
and 9 per 1,000 inhabitants in Eastern Europe)(1). 
In patients with suspected coronary artery disease (CAD) exercise or 
pharmacological stress test are indicated for diagnostic work-up, as 
suggested by the recent European(2) and American Guidelines(3). As 
described by Nesto et al in the late 1980s, the ischemic cascade is a 
temporal sequence of hemodynamic, electrocardiographic abnormalities 
and symptoms(4), and subendocardial and transmural perfusion defects 
are the fi rst expression of the imbalance between myocardial oxygen 
supply and demand. Perfusion imaging, therefore, has a central role in 
investigation and management of patients with possible or actual 
coronary artery disease.
MYOCARDIAL PERFUSION IMAGING                            
Different non-invasive imaging modalities can evaluate myocardial 
perfusion by assessing the functional signifi cance of epicardial coronary 
stenoses by demonstrating stress-induced ischemia (perfusion 
abnormalities) in coronary artery disease (CAD). Stress imaging 
techniques have advantages over the conventional exercise electro-
cardiogram, particularly superior diagnostic performance for detection 
of obstructive coronary disease and the ability to localize and quantify 
areas of ischemia(2). When luminal obstruction is <50%, maximal fl ow 
during exercise can be maintained. Coronary stenosis of >50% may be 
associated with ischemia as coronary blood fl ow becomes inadequate 
to meet cardiac metabolic demand during stress(5,6). Although physical 
exercise is the most physiologic stimulus to induce myocardial 
hyperemia, pharmacological stress testing offers an effective alternative. 
Current clinically available techniques to evaluate myocardial perfusion 
are positron emission tomography (PET), single photon emission 
computed tomography (SPECT), myocardial contrast echocardiography 
(MCE), and recently cardiovascular magnetic resonance (CMR). 
Although PET is considered the gold standard technique, due to 
its ability to quantify absolute myocardial perfusion in ml/min/g of 
myocardium, this test is not widely available, it is expensive, and it uses 
ionising-radiation exposure. Its sensitivity and specifi city for the 
detection of CAD is 79% and 85%, respectively(7). 
SPECT is the most widely available myocardial perfusion test, it has 
been well validated and it has high sensitivity (mean values, 87-89%) for 
detection of coronary artery disease but lower specifi city (mean values, 
73-75%)(2,8). However, this imaging modality is limited by a considerable 
radiation burden, relatively poor spatial resolution (approximately 
10mm), attenuation artefact caused by soft tissues, and long duration of 
the scan (4-6 hours for stress and rest scans). MCE can assess myocardial 
perfusion(9) and has the advantages of easier access and affordability, but 
is signifi cantly operator dependent and requires good echocardiographic 
windows.
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 Perfusion CMR is an attractive imaging modality 
that is becoming comparable with other clinically diagnostic tests. 
SPECT and PET are well clinically validated and have good accuracy 
for detection of signifi cant CAD. However, these techniques have a 
rather low spatial resolution and are not suitable for the detection 
of subendocardial perfusion defect. In addition, the radiation burden, 
the potential for attenuation artefacts (SPECT) and the limited 
availability (PET) are limitations of these imaging techniques. An 
integrated assessment of myocardial perfusion, function and viability 
is feasible with CMR. In addition, compared to other clinically 
available imaging techniques, CMR perfusion has excellent spatial 
resolution and no ionising radiation exposure. However, it is not 
widely available and there is a need of protocol and pulse sequence 
standardization. 
Most perfusion analysis remains observer-dependent (“eyeball” 
analysis) or dependent on bolus dispersion (semi-quantitative 
analysis). Fully quantitative analysis using CMR perfusion is currently 
time-consuming for clinical application. Perfusion CMR is an evolving 
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CMR perfusion imaging is an innovative and promising technique 
offering high spatial resolution (2mm) without ionizing radiation 
exposure and its use is rapidly evolving in the diagnosis and management 
of patients with CAD. During a single scan of 1 hour duration, 
information can be gained on: 1) regional and global myocardial function; 
2) myocardial perfusion in regions supplied by normal or diseased 
arteries, both during stress and at rest; 3) the presence of intracavitary 
thrombus or microvascular obstruction in the setting of acute myocardial 
infarction (early gadolinium-enhancement imaging); 4) detection of 
myocardial infarction (late gadolinium-enhancement imaging); and 
5) evaluation of myocardial viability(10).
The fi rst CMR perfusion study was described in 1987 by Johnston et 
al.(11) that reported the potential applications and limitations of 
gadolinium-diethylenetriamine pentaacetic acid (DTPA) as a myocardial 
perfusion agent in an animal model of coronary occlusion. Quantifi cation 
of myocardial blood fl ow by fi rst-pass myocardial perfusion imaging was 
consequently validated against microspheres(12,13). The clinical feasibility 
of the technique in humans was demonstrated in the early 1990s by 
several groups(14,15), and from this time the perfusion CMR literature has 
mainly been directed towards improving the technical robustness of 
the technique and validating it against other clinically available perfusion 
imaging modalities such as SPECT and PET. 
This paper will review the role of CMR fi rst-pass myocardial perfusion 
from the technical aspects of image acquisition and image analysis to 
the clinical applications in patients with coronary artery disease. 
CMR TECHNIQUE                                                              
1. Contrast agents  
Gadolinium-chelate contrast agents, such as Gd-DTPA, are extracellular 
paramagnetic contrast agents that accentuate the difference in tissue 
relaxation characteristics. Following intravenous administration, the 
contrast agent diffuses rapidly from the intravascular to the extracellular 
compartment. The corresponding increased image intensity is the result 
of the shortening of myocardial T1 relaxation time caused by the 
contrast agent, and the magnitude of the signal enhancement depends 
on the amount of contrast agent present. 
Myocardial perfusion imaging
Early studies in CMR myocardial perfusion with gadolinium-chelates 
showed that the overall image intensity is a function of several 
parameters, including the delivery and the dose of the contrast agent(16). 
In general, lower doses cause lower signal to noise (SNR) in the 
myocardium, whereas higher doses determine a non-linear signal 
intensity in the left ventricular cavity (after contrast administration) 
resulting in an inaccurate input function. The optimal dose of contrast 
agent for perfusion CMR has not been determined, but a number of 
studies have helped identify the correct range. The best dose of 
gadodiamide for visual assessment of stress-induced regional perfusion 
abnormalities was identifi ed with 0.1mmol/kg bodyweight (as opposed 
to 0.05 and 0.15mmol/kg bodyweight) using a GRE-EPI (Gradient 
Echo-Echo Planar Imaging) sequence(17). Superior image quality was 
found with an SSFP (Steady State Free Precession) sequence with both 
dosage regimes of 0.05mmol/kg and 0.025mmol/kg bodyweight for Gd-
BOPTA, in comparison with T1-GRE or GRE-EPI sequences(18). In a 
multicentre dose-ranging study it was established that the minimally 
effi cacious dose of Gd-DTPA for detecting obstructive coronary artery 
disease was 0.05mmol/kg (mean sensitivity 93±0%, mean specifi city 
75±7% and mean accuracy 85±3%)(19) when compared to 0.10 and 
0.15mmol/kg. In this study, higher doses yielded greater myocardial 
enhancement but did not result in higher diagnostic accuracy. This is 
most likely due to the fact that higher contrast doses are more likely to 
cause susceptibility artefacts that could be mistakenly read as real 
perfusion defects. The same images were analysed using upslope analysis 
and a higher sensitivity and specifi city was found at 0.1mmol/kg than at 
0.05mmol/Kg (but again, lower specifi city at 0.15mmol/kg)(20). 
A second important parameter is the injection rate of the contrast 
agent bolus. This has not been standardized yet and it varies between 
centres from 3.5ml/s to 8ml/sec. In healthy myocardial segments, the 
myocardial enhancement is largely independent from the injection rate 
of the contrast agent bolus, as long as the injection speed is not below 
4ml/s(18). This is consistent with Elkington et al.(21) who demonstrated 
peak Gd concentration in the ascending aorta at an injection rate 
between 3 and 5ml/s. 
Myocardial viability imaging 
After the perfusion phase, the distribution of gadolinium in the heart is 
determined by the kinetics of access to different tissue types. Access 
(wash-in) to infarcted myocardium is slower, and therefore it has been 
demonstrated that late imaging at 10-20 minutes reveals high signal in 
infarcted tissue (increased volume of distribution), as gadolinium has 
washed out of normal myocardium. This has been validated histologically 
by Kim(22). An improved inversion-recovery gradient-echo pulse 
sequence has the ability to produce a greater difference in signal 
intensity between normal and infarcted myocardium(23). Contrast-
enhanced MR allows the identifi cation of myocardial scar and it is a 
validated method to assess myocardial viability. Other causes of 
abnormal gadolinium uptake are fi brosis or protein deposition in 
cardiomyopathy.
2. Pulse sequences and acceleration factors 
The optimal sequence for myocardial perfusion CMR has not been 
determined. As described by Schwitter(24), the available pulse sequences 
are: 1) Turbo Fast Low-Angle Shot (FLASH), 2) Echo-Planar or Hybrid 
Echo-Planar (EPI) and 3) Steady-State Free Precession (SSFP). The ideal 
sequence for imaging this process should be very rapid, be able to 
“freeze” the cardiac motion, have a high SNR, high spatiotemporal 
resolution and should be robust to artefacts. The current available pulse 
sequences are briefl y described as follows.
FLASH is the simplest method of rapid imaging. It collects one line of 
raw data per radiofrequency excitation, therefore being relatively slow 
and ineffi cient. However, it is considered a robust sequence because 
after each data readout the residual signal is discarded and gets a new 
signal for the next line. This sequence has an intrinsic poor SNR due to 
the low fl ip angle. 
Hybrid EPI requires faster gradients and collects multiple lines of raw 
data after each radiofrequency pulse, and is effectively an accelerated 
variant of the FLASH technique. EPI is a faster sequence with a better 
SNR than FLASH. However, this sequence is prone to off-resonance 
artefacts. These can be reduced by running EPI faster, but at the cost 
of lower SNR.
TrueFISP has a higher SNR due to its higher fl ip angle. It is considered an 
effi cient sequence because it re-uses residual magnetisation. However, 
the image acquisition is slower compared to the other sequences and, 
therefore, prone to motion artefacts as well as being more sensitive to 
off-resonance. Dark ring artefacts had been noted as more prominent 
with TrueFISP(25) (eyeball analysis).
Comparing the 3 sequences, hybrid EPI has the shortest time per 
image, which is important for minimizing cardiac motion artefacts. 
However, in the fastest version with minimal off-resonance errors, 
EPI has lower SNR than the other two sequences. 
The increase in cardiac heart rate that often occurs during hyperemic 
stress may limit the acquisition window, resulting in incomplete 
myocardial coverage. Parallel acquisition methods such as sensitivity 
encoding (SENSE) are used to shorten data acquisition time(26) also in 
CMR(27). The feasibility and high diagnostic accuracy of perfusion CMR 
with SENSE versus conventional angiography has been demonstrated 
in patients with CAD(28). 
The hybrid-EPI is the sequence of choice to perform perfusion CMR, 
both in our centre and in other laboratories(29,30). However, the other 
sequences are still widely used.
3. Adenosine 
Adenosine is an endogenous nucleotide with potent vasodilator 
property in most vascular beds, except in renal afferent arterioles and 
hepatic veins (where it produces vasoconstriction). Adenosine exerts 
its pharmacological effects through activation of purine receptors, 
mainly A1- and A2-adenosine receptors: peripheral vasodilation is the 
effect of the A2-receptor agonism whereas the negative chronotropic, 
dromotropic and inotropic effects on the heart are due to A1-receptor 
activation. 
Normal resting fl ow in the coronary arteries is approximately 1 ml/min/g 
of myocardium. The coronary hyperemia caused by adenosine 
determines an increase in perfusion in normal coronary arteries 
reaching 3-4 ml/min/g, whereas in myocardial territories supplied by 
stenotic vessels perfusion is restricted to resting values of 1 ml/min/g 
(the vessel is already maximally dilated at rest to overcome the limited 
blood fl ow caused by the stenosis)(31). Adenosine causes heterogenous 
myocardial perfusion and this can be detected by perfusion CMR. It can 
also cause ischemia through a transmural “steal phenomenon”. 
Adenosine is infused at the rate of 140 μg ∙ Kg-1 ∙ min-1 using a syringe 
pump. CMR fi rst-pass perfusion acquisition starts 3 minutes after the 
beginning of adenosine infusion. The safety profi le of adenosine in the 
context of stress perfusion imaging was assessed in 9,256 consecutive 
patients undergoing radionuclide imaging(32). Adenosine infusion is safe, 
and its vasodilator and negative dromotropic effects are generally well 
tolerated. Serious side effects are relatively rare, and they rapidly reverse 
with termination of the infusion, due to adenosine’s ultrashort half-life 
(<10 seconds). However, caution should be used because there are 
some reports of the proarrhthymic effects of adenosine(33). 
Dipyridamole is an alternative drug, which increases adenosine through 
indirect mechanisms. It is actively metabolized in the liver and, therefore, 
its vasodilator capacity is variably dependent on individual metabolism 
rate. Compared to adenosine, dypiridamole has a longer half-life 
(30 minutes), and prolonged side effects. Typically, the infusion dose is 
0.56 mg ∙ Kg-1 ∙ min-1 for 4 minutes and the images acquisition starts 
after 6 minutes. Compared to dypiridamole, adenosine has been shown 
to lower costs both for patients’ monitoring and adverse events 
management(34). 
Adenosine or dobutamine stress CMR perfusion?
Adenosine has a more favorable safety profi le and is well established 
for the assessment of myocardial perfusion, both with echocardiography 
and nuclear cardiac imaging. 
In 79 consecutive patients with suspected or known CAD (but no 
history of myocardial infarction) the diagnostic value of inducible wall 
motion abnormalities during dobutamine or adenosine stress CMR 
were compared with invasive coronary angiography(35). Dobutamine 
showed to be superior (sensitivity: 89%, specifi city: 80%) for the 
detection of inducible wall motion abnormalities compared to 
adenosine (sensitivity: 40%, specifi city: 96%) in patients with epicardial 
coronary stenosis >50% luminal narrowing. Adenosine stress CMR 
wall motion was highly specifi c, because it identifi ed only patients with 
high-grade coronary stenosis (>75% luminal narrowing). Visual 
assessment of adenosine stress perfusion defects had a good sensitivity 
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4. Imaging protocol 
Typically, 3 short-axis slices (basal, mid-cavity and apical) are acquired 
both during stress and at rest, in order to provide complete myocardial 
segmental coverage, according to the recommended 17-segment 
myocardial model for the tomographic imaging of the heart(36). And 
although there is variability in the coronary blood supply to myocardial 
segments, the 17 myocardial segments are assigned to one of the three 
major coronary arteries(36). The 3 short axis images are acquired 
throughout the cardiac cycle and triggered to the R wave on the ECG 
tracing; approximately 40-60 images for each slice location. Breathing 
should be suspended for at least the early part of the image acquisition 
(during the fi rst pass) to minimize breathing motion artefacts and 
facilitate diagnostic interpretation. The short-axis planes can evaluate 
only 16 myocardial segments, failing to assess the ventricular apex. A 
combined long- and short-axis imaging protocol has been proposed; 
however, the long-axis views were not able to depict inducible perfusion 
defects in the apex, despite apical ischemia being demonstrated with 
recent SPECT in the same patients(37). The number of short-axis slices 
is strictly limited by the patient’s heart rate, i.e. bradycardia could allow 
the acquisition of extra slices. Fifty cardiac cycles are acquired to allow 
the complete track of the dynamic process of contrast bolus from the 
moment of the peripheral injection to the diffusion in the myocardium 
of the left ventricle. Probably only 30 cardiac cycles are needed, but the 
exact arrival time of the bolus is unpredictable. 
Resting perfusion images are acquired 20 minutes after the stress 
perfusion images, a time window to allow partial contrast wash-out 
from the previous injection. 
Interpretation algorithm: stress-rest or stress-late gadolinium 
enhancement
With CMR, the rest imaging assesses the resting perfusion, and the stress 
imaging shows myocardial perfusion during hyperemia. This is in 
distinction to perfusion SPECT where the both rest and stress imaging 
are strongly modulated by myocardial viability. Therefore, the stress-rest 
protocol in CMR resembles more the PET approach to calculate the 
perfusion reserve. An alternative approach combines myocardial 
perfusion at stress to assess myocardial ischemia and late-gadolinium 
enhancement to probe myocardial viability(38). The reported sensitivity, 
specifi city and accuracy of the combined diagnostic approach was 89%, 
87% and 88%, respectively compared to perfusion CMR alone (84%, 58% 
and 68%, respectively). The ideal protocol requires further research, 
but for simplicity the stress/late enhancement approach is the most 
attractive. 
5. Image analysis 
The measurement of absolute tissue perfusion by CMR remains a 
more diffi cult but very desirable goal. Whether the efforts to apply 
quantitative analysis provide signifi cantly improved accuracy of the 
technique or whether it helps only to ameliorate the variability and bias 
of less experienced readers is still unclear(39). Even though this argument 
has been made for cardiac nuclear studies, it may well be applied to 
CMR fi rst-pass perfusion imaging. Analysis is either visual to identify 
areas of low signal representing reduced myocardial perfusion, or 
quantitative with dedicated computer software.
Qualitative analysis
A rapid visual assessment is considered more appropriate for a clinical 
application of the imaging technique. Perfusion defects are defi ned as 
focal areas of diminished myocardial enhancement, which therefore 
appear hypointense (darker) compared to normal segments (Figure 1). 
In a study comparing the perfusion CMR fi ndings with angiography, the 
sensitivity and specifi city of visual assessment was 93% and 60%, 
respectively(40). Qualitative MR reporting was possible in 98% of the 
cases. As for other imaging techniques, the qualitative approach is observer-
dependent and potentially less accurate than the quantitative analysis. 
CASE A: subendocardial perfusion defect in the lateral 
and inferior walls extending to the inferior septum; 
subsequent coronary angiography showed stenosis 
of the mid right coronary artery and proximal left 
circumﬂ ex coronary artery.
FIGURE 1: First-pass CMR perfusion during adenosine stress, mid-cavity slices. 
CASE B: subendocardial perfusion defect in the lateral 
wall; coronary angiography conﬁ rmed 90% stenosis of 
the ﬁ rst obtuse marginal branch.
CASE C: extensive perfusion defect in the anterior 
septum; coronary angiography showed 85% stenosis of 
the mid left anterior descending coronary artery.
8Quantitative analysis
Quantitative analysis aims to remove dependence on observer and on 
bolus dispersion. 
Myocardial perfusion reserve (MPR) was proposed since the early 
1970s as an index of functional severity of coronary stenosis(41,42), and 
it is calculated as the ratio of hyperemic and baseline myocardial 
blood fl ow. In humans, PET is the only validated imaging method to 
measure quantitative myocardial blood fl ow and MPR(43). Cullen et al. 
demonstrated the feasibility of performing myocardial perfusion reserve 
index measurement by fi rst-pass CMR in normal volunteers and 
patients with CAD(44) compared to quantitative angiography and PET 
data. Similar reliable assessment of MPR index by CMR perfusion in a 
clinical context was reported by other groups(45). Some preliminary 
steps need to be taken before performing the quantitative analysis: data 
should be corrected for respiratory motion and coil sensitivity, then 
signal intensities should be converted into contrast agent concentration 
in order to allow for input correction. 
For the analysis, the left ventricle is divided into regions of interest (ROI), 
according to the 17-segments model(36). Endocardial and epicardial 
contours are traced on each image and the signal intensity over time 
(upslope), arrival time, time to peak signal, mean transit time (MTT) are 
calculated for each ROI. Then different models may be applied to 
calculated perfusion(46): fully quantitative or semi-quantitative analysis. 
The latter aims to remove operator-dependence, whereas the fully 
quantitative analysis removes dependence on bolus dispersion as well. 
For the semi-quantitative analysis the upslope of the signal-intensity 
curve is the most widely used parameter, being also the most sensitive 
parameter to differences in myocardial blood fl ow(46). Additionally, 
it correlates closely with microspheres (in dogs)(47,48), and PET 
measurements (in humans)(49). An underestimation of coronary fl ow 
reserve by CMR perfusion measurements compared to PET was 
reported by Ibrahim et al. in patients with angiographically docu-
mented CAD(50). The upslope index yielded a sensitivity, specifi city and 
diagnostic accuracy of 69%, 89% and 79%, respectively, for the 
localization of coronary artery stenosis (>75%, MPR <1.2) and a 
sensitivity, specifi city and diagnostic accuracy of 86%, 84% and 
85%, respectively, for detection of reduced coronary fl ow reserve 
(PET<2.0, MPR<1.3).
The signal intensity (SI) curve is a combination of perfusion and diffusion, 
both of which are infl uenced by blood fl ow(51). The early phase of SI-
time curve is mainly infl uenced by perfusion and to a lesser extent by 
diffusion, and the latter parts are increasingly infl uenced by diffusion. 
Both the wash-in and wash-out are strongly infl uenced by the 
compactness of the contrast bolus, and for a reliable calculation it 
should be small and compact. Ischemic myocardial segments show a 
slower passage of the contrast agent(52), (lower peak myocardial signal 
intensity, slower rate of signal increase and longer time to peak 
perfusion), resulting in a stronger infl uence of diffusion and a less 
pronounced or even nonexistent downslope. A linear fi t of the 
upslope of the signal intensity-time curve was proposed by Al-Saadi as 
a new and easy method for the determination of MPR(53) and to 
minimize the infl uence of diffusion. This parameter was demonstrated 
to be highly reproducible, with good interobserver and intraobserver 
variability. 
Fully quantitative analysis can be achieved by normalized upslope or full 
deconvolution analysis(54) constrained by a mathematical model of 
contrast agent kinetics. A requirement for quantitative perfusion is to 
maintain a linear relationship between SI and contrast concentration 
(maintained only by low contrast concentration)(46), especially for the 
arterial input function. 
However, the improvement of contrast to noise ratio is dependent on 
the use of higher contrast agent dose. In order to overcome this 
problem, Christian et al.(47) introduced the dual-bolus injection technique 
that allows measurement of the input function with a low-dosage 
contrast injection, followed by the measurement of myocardial contrast 
enhancement with a higher bolus dosage. Hsu and colleagues reported 
that, in healthy human subjects, rest and stress myocardial blood fl ow 
and MPR evaluated by dual-bolus perfusion MRI were similar to 
published data, whereas semiquantitative methods such as the upslope 
index were signifi cantly underestimating MPR(54). With a new method 
of assessing arterial input function, myocardial perfusion reserve (MPR) 
can also be achieved by a single bolus technique with a high dose 
gadolinium(55). 
Overall, fi rst-pass perfusion CMR can feasibly evaluate the subendo-
cardial layer and assess MPR; however, this qualitative approach can be 
time-consuming and not always reproducible. 
6. Clinical applications 
Clinical applications of CMR perfusion have been described since the 
year 2000. Al-Saadi evaluated 15 patients with single-vessel CAD and 
5 controls without signifi cant CAD using fi rst-pass perfusion CMR(53). 
He concluded that the technique yielded a high sensitivity, specifi city 
and diagnostic accuracy (90%, 83% and 87%, respectively). Interobserver 
and intraobserver variability were low (r=0.96 and 0.99). Schwitter et 
al. assessed myocardial perfusion in patients with CAD and healthy 
subjects comparing perfusion CMR, PET and coronary angiography(49). 
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upslope showed that perfusion CMR had a high sensitivity (91%) and 
specifi city (94%) for CAD defi ned by PET (coronary fl ow reserve 
<1.65 in ≥ 1 segment). Similarly, when CAD was assessed by quantitative 
coronary angiography (diameter stenosis ≥ 50% in ≥ 1 artery), perfusion 
CMR demonstrated a sensitivity of 87% and a specifi city of 85%. The 
authors concluded that perfusion CMR may qualify for clinical application 
in the management of CAD because it provides important information 
on the amount of compromised myocardium, even when perfusion 
abnormalities are confi ned to the subendocardial layer. 
Adenosine perfusion CMR has also demonstrated the ability to detect 
subendocardial perfusion defects in patients with cardiac syndrome 
X(56). In 10-matched control patients, myocardial perfusion increased in 
both the endocardium and the epicardium with adenosine. 
Recently, adenosine CMR perfusion demonstrated a high negative 
predictive value in patients presenting to an emergency department with 
chest pain, negative troponin and non-diagnostic electrocardiogram(57). 
None of the subjects with normal adenosine stress CMR scan were 
diagnosed with an adverse cardiac event after 1-year follow-up. 
FUTURE DIRECTIONS                                                     
Selective adenosine A2A receptor agonists currently in development may 
play an important role for cardiac perfusion imaging. Initial clinical 
experiences reported this new agent as effective as adenosine in 
detecting and quantifying perfusion defects with a concomitant 
reduction in incidence and severity of side effects and simplicity of 
bolus administration(58,59). In addition, the simplifi ed logistics of the drug 
delivery (i.e. no need of infusion pump and long tubing to reach the 
patient in the magnet) and the potential use in asthmatic patients make 
this new agent represent an attractive alternative. 
Limited data are available regarding the application of intravascular 
gadolinium-based contrast media. Intravascular contrast media yield 
lower signal intensity in the myocardium than extracellular contrast 
agents because of reduced exchange into the extracellular space during 
the fi rst pass(24). Dose effects on peak signal enhancement have been 
described in inversion recovery EPI using intra- and extravascular 
gadolinium-based contrast agents(60). Jerosch-Herold et al. have 
demonstrated that perfusion index with an intravascular contrast 
agent (MS-325) is accurately estimated if corrected by the time-to-
maximum upslope(61). Currently, the value of quantitative perfusion with 
intravascular contrast agent in humans with CAD is not known. 
A recent paper by Saeed and coworkers described the combination of 
intravascular and extracellular Gd-chelates in discriminating acute from 
chronic infarctions on late enhancement images in an experimental 
animal model(62). There was no late enhancement produced by 
intravascular Gd-chelate in chronic infarction, likely due to poor 
vascularization and perfusion in scar tissue. 
The role of 3 Tesla magnets for myocardial perfusion remains to be 
evaluated. Some early investigations of 3T versus 1.5 T are showing the 
predictable benefi t of the higher SNR at 3T(63). 
As in SPECT, an agent that could directly assess areas of ischemia which 
persist after stress is highly desirable for CMR, so that fi rst-pass imaging 
is not needed. Manganese is a paramagnetic ion with pharmacokinetic 
properties similar to those of 99mTC-sestamibi and there are 
experimental studies with manganese-enhanced CMR(64). However, the 
cardiotoxic and cardio depressant effects of manganese(65) make its 
clinical application not feasible at this time. 
Blood oxygen level dependent (BOLD) CMR is an interesting technique 
with the potential to identify areas of myocardial ischemia(66,67), as signal 
changes within the myocardium based on changes in deoxyhaemoglobin, 
without using contrast media(68). However, large comparative studies 
with gold standard methods of myocardial ischemia are required. 
CONCLUSIONS                                                                  
Perfusion CMR is an attractive imaging modality, which is becoming 
comparable with other clinically diagnostic tests. SPECT and PET are 
well clinically validated and have good accuracy for detection of 
signifi cant CAD. However, these techniques have a rather low spatial 
resolution and are not suitable for the detection of subendocardial 
perfusion defect. In addition, the radiation burden, the potential for 
attenuation artefacts (SPECT) and the limited availability (PET) are 
limitations of these imaging techniques. An integrated assessment of 
myocardial perfusion, function and viability is feasible with CMR. In 
addition, compared to other clinically available imaging techniques, CMR 
perfusion has excellent spatial resolution and no ionising radiation 
exposure. However, it is not widely available and there is a need of 
protocol and pulse sequence standardization. 
Most perfusion analysis remains observer-dependent (“eyeball” analysis) 
or dependent on bolus dispersion (semi-quantitative analysis). Fully 
quantitative analysis using CMR perfusion is currently time-consuming 
for clinical application. 
Perfusion CMR is an evolving fi eld with numerous future directions. 
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